NO20016246L - Selektiv iGluR5 reseptorantagonist for behandling av migrene - Google Patents

Selektiv iGluR5 reseptorantagonist for behandling av migrene

Info

Publication number
NO20016246L
NO20016246L NO20016246A NO20016246A NO20016246L NO 20016246 L NO20016246 L NO 20016246L NO 20016246 A NO20016246 A NO 20016246A NO 20016246 A NO20016246 A NO 20016246A NO 20016246 L NO20016246 L NO 20016246L
Authority
NO
Norway
Prior art keywords
migraine
treatment
receptor antagonist
iglur5 receptor
selective iglur5
Prior art date
Application number
NO20016246A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016246D0 (no
Inventor
David Bleakman
Amy Suzon Chappell
Sandra Ann Filla
Kirk Willis Johnson
Paul Leslie Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20016246D0 publication Critical patent/NO20016246D0/no
Publication of NO20016246L publication Critical patent/NO20016246L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20016246A 1999-07-06 2001-12-19 Selektiv iGluR5 reseptorantagonist for behandling av migrene NO20016246L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27
PCT/US2000/016297 WO2001001972A2 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (2)

Publication Number Publication Date
NO20016246D0 NO20016246D0 (no) 2001-12-19
NO20016246L true NO20016246L (no) 2002-03-04

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016246A NO20016246L (no) 1999-07-06 2001-12-19 Selektiv iGluR5 reseptorantagonist for behandling av migrene

Country Status (28)

Country Link
US (4) US6566370B1 (cs)
EP (1) EP1200073B1 (cs)
JP (1) JP4619595B2 (cs)
KR (1) KR20020024300A (cs)
CN (1) CN1230174C (cs)
AR (1) AR029373A1 (cs)
AU (1) AU773304B2 (cs)
BR (1) BR0012175A (cs)
CA (1) CA2378613C (cs)
CZ (1) CZ20014488A3 (cs)
DE (1) DE60032905T2 (cs)
DK (1) DK1200073T3 (cs)
DZ (1) DZ3209A1 (cs)
EA (1) EA004290B1 (cs)
ES (1) ES2278619T3 (cs)
HK (1) HK1047036A1 (cs)
HR (1) HRP20020013A2 (cs)
HU (1) HUP0202253A3 (cs)
IL (1) IL146697A0 (cs)
MX (1) MXPA01012726A (cs)
MY (1) MY133503A (cs)
NO (1) NO20016246L (cs)
NZ (1) NZ515616A (cs)
PE (1) PE20010299A1 (cs)
PT (1) PT1200073E (cs)
SK (1) SK112002A3 (cs)
TR (1) TR200200066T2 (cs)
WO (1) WO2001001972A2 (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046173A1 (en) * 1999-12-22 2001-06-28 Eli Lilly And Company SELECTIVE iGLUR5 RECEPTOR ANTAGONISTS
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP1351952A2 (en) * 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
DE60134427D1 (de) * 2001-01-05 2008-07-24 Lilly Co Eli Exzitatorische aminosäure-rezeptor-antagonisten
DZ3460A1 (fr) * 2001-01-05 2002-07-11 Lilly Co Eli Antagonistes du recepteur d'acide amine excitateur
WO2002053555A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
WO2002053139A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
EA009526B1 (ru) 2002-04-26 2008-02-28 Эли Лилли Энд Компани Сложноэфирные производные декагидроизохинолин-3-карбоновой кислоты в качестве анальгетиков
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
JP7399096B2 (ja) 2018-03-05 2023-12-15 ヤンセン ファーマシューティカ エヌ．ベー． 神経変性を検出するためのアッセイ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US6242462B1 (en) * 1997-04-07 2001-06-05 Eli Lilly And Company Pharmacological agents
US6486175B1 (en) * 1999-07-06 2002-11-26 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid

Also Published As

Publication number Publication date
JP4619595B2 (ja) 2011-01-26
ES2278619T3 (es) 2007-08-16
CN1359289A (zh) 2002-07-17
EP1200073A2 (en) 2002-05-02
HUP0202253A2 (hu) 2002-11-28
EA200200132A1 (ru) 2002-06-27
US7157582B2 (en) 2007-01-02
MXPA01012726A (es) 2002-07-02
DZ3209A1 (fr) 2001-01-11
CA2378613A1 (en) 2001-01-11
US6855823B2 (en) 2005-02-15
AU773304B2 (en) 2004-05-20
AR029373A1 (es) 2003-06-25
BR0012175A (pt) 2002-03-05
EA004290B1 (ru) 2004-02-26
EP1200073B1 (en) 2007-01-10
HRP20020013A2 (en) 2003-08-31
US6566370B1 (en) 2003-05-20
SK112002A3 (en) 2003-05-02
NZ515616A (en) 2004-05-28
WO2001001972A3 (en) 2001-12-06
US20040192722A1 (en) 2004-09-30
AU5873200A (en) 2001-01-22
DE60032905T2 (de) 2007-10-18
DK1200073T3 (da) 2007-05-07
PE20010299A1 (es) 2001-03-07
CN1230174C (zh) 2005-12-07
DE60032905D1 (de) 2007-02-22
KR20020024300A (ko) 2002-03-29
NO20016246D0 (no) 2001-12-19
HUP0202253A3 (en) 2003-12-29
JP2003503449A (ja) 2003-01-28
CA2378613C (en) 2007-10-02
US20050159445A1 (en) 2005-07-21
PT1200073E (pt) 2007-03-30
MY133503A (en) 2007-11-30
WO2001001972A2 (en) 2001-01-11
HK1047036A1 (zh) 2003-02-07
CZ20014488A3 (cs) 2003-01-15
US6759418B2 (en) 2004-07-06
IL146697A0 (en) 2002-07-25
TR200200066T2 (tr) 2002-04-22
US20030199546A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
NO20016246L (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
NO20022925D0 (no) EP4 reseptor selektive agonister for behandling av osteoporose
NO20032360L (no) EP4 reseptor selektive agonister for behandling av osteoporose
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
PT1224174E (pt) Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
CY2010003I1 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
DE60026169D1 (de) Selektive neurokinin-antagonisten
PT1189916E (pt) N-pirazole agonistas do receptor a2a
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
DK1218382T3 (da) Bicykliske imidazo-3-ylaminderivater
DE50015443D1 (de) Bicyclische imidazo-5-yl-aminderivate
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
NO20015779L (no) Bradykinin-reseptorantagonister
NO20013997L (no) Reseptoranalyse
IT1316831B1 (it) Dispositivo per il collegamento di due parti costruttive
NO20052012L (no) Indoler nyttige for behadling av androgen-reseptor relaterte sykdommer
DE60016769D1 (de) Antagonisten des vitronectin-receptors
NO20005386D0 (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
NO20030717L (no) Forbindelser for behandling av avhengighetsforstyrrelser
IS5897A (is) Úreídópíperidín afleiður sem valvís NK3 viðtakamótlyf fyrir manneskjur
NO20022142L (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
NO990382D0 (no) Innretning for demineralisering av vann
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application